The interferon regulatory factors as novel potential targets in the treatment of cardiovascular diseases

British Journal of Pharmacology

Volumn 172, Issue 23, 2015, Pages 5457-5476

  Zhang, Xiao Jing ^a,b   Jiang, Ding Sheng ^a   Li, Hongliang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b University of Macau   (Macao)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON CONSENSUS SEQUENCE BINDING PROTEIN; INTERFERON REGULATORY FACTOR; INTERFERON REGULATORY FACTOR 1; INTERFERON REGULATORY FACTOR 2; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 4; INTERFERON REGULATORY FACTOR 5; INTERFERON REGULATORY FACTOR 7; INTERFERON REGULATORY FACTOR 9; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 9;

ABDOMINAL AORTA ANEURYSM; ADAPTIVE IMMUNITY; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; CYTOKINE RELEASE; DENDRITIC CELL; GENETIC ASSOCIATION; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; INTERFERON PRODUCTION; MYELOID PROGENITOR CELL; NATURAL KILLER CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ACETYLATION; REVIEW; UBIQUITINATION; VASCULAR REMODELING; VASCULAR SMOOTH MUSCLE CELL; VIRUS INFECTION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASES; GENETICS; METABOLISM;

CARDIOVASCULAR DISEASES; HUMANS; INTERFERON REGULATORY FACTORS;

EID: 84949529544     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12881     Document Type: Review

References (227)

1. Akira S, Uematsu S, Takeuchi O, (2006). Pathogen recognition and innate immunity. Cell 124: 783-801.
2. Alexander M, Forster C, Sugimoto K, Clark HB, Vogel S, Ross ME, et al. (2003). Interferon regulatory factor-1 immunoreactivity in neurons and inflammatory cells following ischemic stroke in rodents and humans. Acta Neuropathol 105: 420-424.
3. Alexander MR, Owens GK, (2012). Epigenetic control of smooth muscle cell differentiation and phenotypic switching in vascular development and disease. Annu Rev Physiol 74: 13-40.
4. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Catalytic Receptors. Br J Pharmacol 170: 1676-1705.
5. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
6. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
7. Balkhi MY, Fitzgerald KA, Pitha PM, (2008). Functional regulation of MyD88-activated interferon regulatory factor 5 by K63-linked polyubiquitination. Mol Cell Biol 28: 7296-7308.
8. Banchereau J, Pascual V, (2006). Type I interferon in systemic lupus erythematosus and other autoimmune diseases. Immunity 25: 383-392.
9. Barro M, Patton JT, (2005). Rotavirus nonstructural protein 1 subverts innate immune response by inducing degradation of IFN regulatory factor 3. Proc Natl Acad Sci U S A 102: 4114-4119.
10. Bauhofer O, Summerfield A, Sakoda Y, Tratschin JD, Hofmann MA, Ruggli N, (2007). Classical swine fever virus Npro interacts with interferon regulatory factor 3 and induces its proteasomal degradation. J Virol 81: 3087-3096.
11. Becker AM, Michael DG, Satpathy AT, Sciammas R, Singh H, Bhattacharya D, (2012). IRF-8 extinguishes neutrophil production and promotes dendritic cell lineage commitment in both myeloid and lymphoid mouse progenitors. Blood 119: 2003-2012.
12. Ben-Neriah Y, (2002). Regulatory functions of ubiquitination in the immune system. Nat Immunol 3: 20-26.
13. van Berlo JH, Maillet M, Molkentin JD, (2013). Signaling effectors underlying pathologic growth and remodeling of the heart. J Clin Invest 123: 37-45.
14. Biggs LC, Naridze RL, DeMali KA, Lusche DF, Kuhl S, Soll DR, et al. (2014). Interferon regulatory factor 6 regulates keratinocyte migration. J Cell Sci 127 (Pt 13): 2840-2848.
15. Brown J, Wang H, Hajishengallis GN, Martin M, (2011). TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk. J Dent Res 90: 417-427.
16. Caillaud A, Prakash A, Smith E, Masumi A, Hovanessian AG, Levy DE, et al. (2002). Acetylation of interferon regulatory factor-7 by p300/CREB-binding protein (CBP)-associated factor (PCAF) impairs its DNA binding. J Biol Chem 277: 49417-49421.
17. Camoretti-Mercado B, Dulin NO, Solway J, (2003). Serum response factor function and dysfunction in smooth muscle. Respir Physiol Neurobiol 137: 223-235.
18. Candelario-Jalil E, (2009). Injury and repair mechanisms in ischemic stroke: considerations for the development of novel neurotherapeutics. Curr Opin Investig Drugs 10: 644-654.
19. Caso JR, Pradillo JM, Hurtado O, Lorenzo P, Moro MA, Lizasoain I, (2007). Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 115: 1599-1608.
20. Chamorro A, Meisel A, Planas AM, Urra X, van de Beek D, Veltkamp R, (2012). The immunology of acute stroke. Nat Rev Neurol 8: 401-410.
21. Chen HW, King K, Tu J, Sanchez M, Luster AD, Shresta S, (2013a). The roles of IRF-3 and IRF-7 in innate antiviral immunity against dengue virus. J Immunol 191: 4194-4201.
22. Chen HZ, Guo S, Li ZZ, Lu Y, Jiang DS, Zhang R, et al. (2014). A critical role for interferon regulatory factor 9 in cerebral ischemic stroke. J Neurosci 34: 11897-11912.
23. Chen K, Gao L, Liu Y, Zhang Y, Jiang DS, Wei X, et al. (2013b). Vinexin-beta protects against cardiac hypertrophy by blocking the Akt-dependent signalling pathway. Basic Res Cardiol 108: 338.
24. Chen Z, Rijnbrand R, Jangra RK, Devaraj SG, Qu L, Ma Y, et al. (2007). Ubiquitination and proteasomal degradation of interferon regulatory factor-3 induced by Npro from a cytopathic bovine viral diarrhea virus. Virology 366: 277-292.
25. Clark K, Takeuchi O, Akira S, Cohen P, (2011). The TRAF-associated protein TANK facilitates cross-talk within the IkappaB kinase family during Toll-like receptor signaling. Proc Natl Acad Sci U S A 108: 17093-17098.
26. Colonna M, (2007). TLR pathways and IFN-regulatory factors: to each its own. Eur J Immunol 37: 306-309.
27. Cui G, Ye X, Zuo T, Zhao H, Zhao Q, Chen W, et al. (2013). Chloroquine pretreatment inhibits Toll-like receptor 3 signaling after stroke. Neurosci Lett 548: 101-104.
28. Cunninghame Graham DS, Manku H, Wagner S, Reid J, Timms K, Gutin A, et al. (2007). Association of IRF5 in UK SLE families identifies a variant involved in polyadenylation. Hum Mol Genet 16: 579-591.
29. Daffis S, Samuel MA, Keller BC, Gale M Jr, Diamond MS, (2007). Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms. PLoS Pathog 3: e106.
30. Daffis S, Samuel MA, Suthar MS, Keller BC, Gale M Jr, Diamond MS, (2008). Interferon regulatory factor IRF-7 induces the antiviral alpha interferon response and protects against lethal West Nile virus infection. J Virol 82: 8465-8475.
31. Daffis S, Suthar MS, Szretter KJ, Gale M Jr, Diamond MS, (2009). Induction of IFN-beta and the innate antiviral response in myeloid cells occurs through an IPS-1-dependent signal that does not require IRF-3 and IRF-7. PLoS Pathog 5: e1000607.
32. Daffis S, Lazear HM, Liu WJ, Audsley M, Engle M, Khromykh AA, et al. (2011). The naturally attenuated Kunjin strain of West Nile virus shows enhanced sensitivity to the host type I interferon response. J Virol 85: 5664-5668.
33. Davis C, Fischer J, Ley K, Sarembock IJ, (2003). The role of inflammation in vascular injury and repair. J Thromb Haemost 1: 1699-1709.
34. Davis-Dusenbery BN, Wu C, Hata A, (2011). Micromanaging vascular smooth muscle cell differentiation and phenotypic modulation. Arterioscler Thromb Vasc Biol 31: 2370-2377.
35. Di Bernardo MC, Crowther-Swanepoel D, Broderick P, Webb E, Sellick G, Wild R, et al. (2008). A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. Nat Genet 40: 1204-1210.
36. Dimayuga PC, Li H, Chyu KY, Fredrikson GN, Nilsson J, Fishbein MC, et al. (2005). T-cell modulation of intimal thickening after vascular injury: the bimodal role of IFN-gamma in immune deficiency. Arterioscler Thromb Vasc Biol 25: 2528-2534.
37. Drew PD, Franzoso G, Carlson LM, Biddison WE, Siebenlist U, Ozato K, (1995). Interferon regulatory factor-2 physically interacts with NF-kappa B in vitro and inhibits NF-kappa B induction of major histocompatibility class I and beta 2-microglobulin gene expression in transfected human neuroblastoma cells. J Neuroimmunol 63: 157-162.
38. Duan SZ, Usher MG, Mortensen RM, (2008). Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 102: 283-294.
39. Dzau VJ, Braun-Dullaeus RC, Sedding DG, (2002). Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8: 1249-1256.
40. Eguchi J, Yan QW, Schones DE, Kamal M, Hsu CH, Zhang MQ, et al. (2008). Interferon regulatory factors are transcriptional regulators of adipogenesis. Cell Metab 7: 86-94.
41. Eguchi J, Wang X, Yu S, Kershaw EE, Chiu PC, Dushay J, et al. (2011). Transcriptional control of adipose lipid handling by IRF4. Cell Metab 13: 249-259.
42. Elser B, Lohoff M, Kock S, Giaisi M, Kirchhoff S, Krammer PH, et al. (2002). IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity 17: 703-712.
43. Erickson AK, Gale M Jr, (2008). Regulation of interferon production and innate antiviral immunity through translational control of IRF-7. Cell Res 18: 433-435.
44. Eroshkin A, Mushegian A, (1999). Conserved transactivation domain shared by interferon regulatory factors and SMAD morphogens. J Mol Med (Berl) 77: 403-405.
45. Escalante CR, Brass AL, Pongubala JM, Shatova E, Shen L, Singh H, et al. (2002). Crystal structure of PU.1/IRF-4/DNA ternary complex. Mol Cell 10: 1097-1105.
46. Feng D, Sangster-Guity N, Stone R, Korczeniewska J, Mancl ME, Fitzgerald-Bocarsly P, et al. (2010). Differential requirement of histone acetylase and deacetylase activities for IRF5-mediated proinflammatory cytokine expression. J Immunol 185: 6003-6012.
47. Fiedler B, Lohmann SM, Smolenski A, Linnemuller S, Pieske B, Schroder F, et al. (2002). Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc Natl Acad Sci U S A 99: 11363-11368.
48. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. (2003). Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145-1148.
49. Frohlich GM, Meier P, White SK, Yellon DM, Hausenloy DJ, (2013). Myocardial reperfusion injury: looking beyond primary PCI. Eur Heart J 34: 1714-1722.
50. Fu Q, Zhao J, Qian X, Wong JL, Kaufman KM, Yu CY, et al. (2011). Association of a functional IRF7 variant with systemic lupus erythematosus. Arthritis Rheum 63: 749-754.
51. Fujii Y, Shimizu T, Kusumoto M, Kyogoku Y, Taniguchi T, Hakoshima T, (1999). Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences. EMBO J 18: 5028-5041.
52. Gabriele L, Fragale A, Borghi P, Sestili P, Stellacci E, Venditti M, et al. (2006). IRF-1 deficiency skews the differentiation of dendritic cells toward plasmacytoid and tolerogenic features. J Leukoc Biol 80: 1500-1511.
53. Geissmann F, Manz MG, Jung S, Sieweke MH, Merad M, Ley K, (2010). Development of monocytes, macrophages, and dendritic cells. Science 327: 656-661.
54. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, et al. (2002). The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195: 953-958.
55. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, et al. (2014). Executive summary: heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129: 399-410.
56. Graff JW, Ewen J, Ettayebi K, Hardy ME, (2007). Zinc-binding domain of rotavirus NSP1 is required for proteasome-dependent degradation of IRF3 and autoregulatory NSP1 stability. J Gen Virol 88 (Pt 2): 613-620.
57. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, et al. (2006). A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38: 550-555.
58. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, et al. (2005). Involvement of Toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280: 5571-5580.
59. Guo S, Li ZZ, Jiang DS, Lu YY, Liu Y, Gao L, et al. (2014). IRF4 is a novel mediator for neuronal survival in ischaemic stroke. Cell Death Differ 21: 888-903.
60. Halliwell B, (2006). Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658.
61. Hambleton S, Salem S, Bustamante J, Bigley V, Boisson-Dupuis S, Azevedo J, et al. (2011). IRF8 mutations and human dendritic-cell immunodeficiency. N Engl J Med 365: 127-138.
62. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, et al. (1989). Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58: 729-739.
63. Hausenloy DJ, Yellon DM, (2013). Myocardial ischemia-reperfusion injury: a neglected therapeutic target. J Clin Invest 123: 92-100.
64. Heineke J, Molkentin JD, (2006). Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 7: 589-600.
65. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, Yokochi T, et al. (2000). CD8(+) T-cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13: 643-655.
66. Higgs R, Ni Gabhann J, Ben Larbi N, Breen EP, Fitzgerald KA, Jefferies CA, (2008). The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 181: 1780-1786.
67. Higgs R, Lazzari E, Wynne C, Ni Gabhann J, Espinosa A, Wahren-Herlenius M, et al. (2010). Self protection from anti-viral responses-Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-like receptors. PLoS ONE 5: e11776.
68. Hilton L, Moganeradj K, Zhang G, Chen YH, Randall RE, McCauley JW, et al. (2006). The NPro product of bovine viral diarrhea virus inhibits DNA binding by interferon regulatory factor 3 and targets it for proteasomal degradation. J Virol 80: 11723-11732.
69. Hiscott J, (2007). Triggering the innate antiviral response through IRF-3 activation. J Biol Chem 282: 15325-15329.
70. Holland JW, Bird S, Williamson B, Woudstra C, Mustafa A, Wang T, et al. (2008). Molecular characterization of IRF3 and IRF7 in rainbow trout, Oncorhynchus mykiss: functional analysis and transcriptional modulation. Mol Immunol 46: 269-285.
71. Honda K, Taniguchi T, (2006b). IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6: 644-658.
72. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, Mizutani T, et al. (2005). IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
73. Honda K, Takaoka A, Taniguchi T, (2006a). Type I interferon [corrected] gene induction by the interferon regulatory factor family of transcription factors. Immunity 25: 349-360.
74. Honma K, Udono H, Kohno T, Yamamoto K, Ogawa A, Takemori T, et al. (2005). Interferon regulatory factor 4 negatively regulates the production of proinflammatory cytokines by macrophages in response to LPS. Proc Natl Acad Sci U S A 102: 16001-16006.
75. Horiuchi M, Hayashida W, Akishita M, Yamada S, Lehtonen JY, Tamura K, et al. (2000). Interferon-gamma induces AT(2) receptor expression in fibroblasts by JAK/STAT pathway and interferon regulatory factor-1. Circ Res 86: 233-240.
76. Huang H, Tang QZ, Wang AB, Chen M, Yan L, Liu C, et al. (2010). Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling. Hypertension 56: 232-239.
77. Huang J, Liu T, Xu LG, Chen D, Zhai Z, Shu HB, (2005). SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathways. EMBO J 24: 4018-4028.
78. Huang P, Xiao A, Zhou M, Zhu Z, Lin S, Zhang B, (2011). Heritable gene targeting in zebrafish using customized TALENs. Nat Biotechnol 29: 699-700.
79. Huang W, Horvath E, Eklund EA, (2007). PU.1, interferon regulatory factor (IRF) 2, and the interferon consensus sequence-binding protein (ICSBP/IRF8) cooperate to activate NF1 transcription in differentiating myeloid cells. J Biol Chem 282: 6629-6643.
80. Huber M, Brustle A, Reinhard K, Guralnik A, Walter G, Mahiny A, et al. (2008). IRF4 is essential for IL-21-mediated induction, amplification, and stabilization of the Th17 phenotype. Proc Natl Acad Sci U S A 105: 20846-20851.
81. Huye LE, Ning S, Kelliher M, Pagano JS, (2007). Interferon regulatory factor 7 is activated by a viral oncoprotein through RIP-dependent ubiquitination. Mol Cell Biol 27: 2910-2918.
82. Iadecola C, Salkowski CA, Zhang F, Aber T, Nagayama M, Vogel SN, et al. (1999). The transcription factor interferon regulatory factor 1 is expressed after cerebral ischemia and contributes to ischemic brain injury. J Exp Med 189: 719-727.
83. Ichikawa E, Hida S, Omatsu Y, Shimoyama S, Takahara K, Miyagawa S, et al. (2004). Defective development of splenic and epidermal CD4+ dendritic cells in mice deficient for IFN regulatory factor-2. Proc Natl Acad Sci U S A 101: 3909-3914.
84. Inoue T, Croce K, Morooka T, Sakuma M, Node K, Simon DI, (2011). Vascular inflammation and repair: implications for re-endothelialization, restenosis, and stent thrombosis. JACC Cardiovasc Interv 4: 1057-1066.
85. Janeway CA Jr, Medzhitov R, (2002). Innate immune recognition. Annu Rev Immunol 20: 197-216.
86. Jia W, Guo Q, (2008). Gene structures and promoter characteristics of interferon regulatory factor 1 (IRF-1), IRF-2 and IRF-7 from snakehead Channa argus. Mol Immunol 45: 2419-2428.
87. Jiang DS, Bian ZY, Zhang Y, Zhang SM, Liu Y, Zhang R, et al. (2013). Role of interferon regulatory factor 4 in the regulation of pathological cardiac hypertrophy. Hypertension 61: 1193-1202.
88. Jiang DS, Li L, Huang L, Gong J, Xia H, Liu X, et al. (2014a). Interferon regulatory factor 1 is required for cardiac remodeling in response to pressure overload. Hypertension 64: 77-86.
89. Jiang DS, Liu Y, Zhou H, Zhang Y, Zhang XD, Zhang XF, et al. (2014b). Interferon regulatory factor 7 functions as a novel negative regulator of pathological cardiac hypertrophy. Hypertension 63: 713-722.
90. Jiang DS, Luo YX, Zhang R, Zhang XD, Chen HZ, Zhang Y, et al. (2014c). Interferon regulatory factor 9 protects against cardiac hypertrophy by targeting myocardin. Hypertension 63: 119-127.
91. Jiang DS, Wei X, Zhang XF, Liu Y, Zhang Y, Chen K, et al. (2014d). IRF8 suppresses pathological cardiac remodelling by inhibiting calcineurin signalling. Nat Commun 5: 3303.
92. Jiang DS, Zhang XF, Gao L, Zong J, Zhou H, Liu Y, et al. (2014e). Signal regulatory protein-alpha protects against cardiac hypertrophy via the disruption of toll-like receptor 4 signaling. Hypertension 63: 96-104.
93. Kanno Y, Levi BZ, Tamura T, Ozato K, (2005). Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res 25: 770-779.
94. Kano S, Sato K, Morishita Y, Vollstedt S, Kim S, Bishop K, et al. (2008). The contribution of transcription factor IRF1 to the interferon-gamma-interleukin 12 signaling axis and TH1 versus TH-17 differentiation of CD4+ T-cells. Nat Immunol 9: 34-41.
95. Kawai T, Akira S, (2006). TLR signaling. Cell Death Differ 13: 816-825.
96. Kawai T, Sato S, Ishii KJ, Coban C, Hemmi H, Yamamoto M, et al. (2004). Interferon-alpha induction through Toll-like receptors involves a direct interaction of IRF7 with MyD88 and TRAF6. Nat Immunol 5: 1061-1068.
97. Kehat I, Molkentin JD, (2010). Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation 122: 2727-2735.
98. Kikuchi H, Nakayama M, Kuribayashi F, Imajoh-Ohmi S, Nishitoh H, Takami Y, et al. (2014). GCN5 is essential for IRF-4 gene expression followed by transcriptional activation of Blimp-1 in immature B cells. J Leukoc Biol 95: 399-404.
99. Ko J, Gendron-Fitzpatrick A, Splitter GA, (2002). Susceptibility of IFN regulatory factor-1 and IFN consensus sequence binding protein-deficient mice to brucellosis. J Immunol 168: 2433-2440.
100. Kong HJ, Anderson DE, Lee CH, Jang MK, Tamura T, Tailor P, et al. (2007). Cutting edge: autoantigen Ro52 is an interferon inducible E3 ligase that ubiquitinates IRF-8 and enhances cytokine expression in macrophages. J Immunol 179: 26-30.
101. Kong Y, Tannous P, Lu G, Berenji K, Rothermel BA, Olson EN, et al. (2006). Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy. Circulation 113: 2579-2588.
102. Korachi M, Ceran N, Adaleti R, Nigdelioglu A, Sokmen M, (2013). An association study of functional polymorphic genes IRF-1, IFNGR-1, and IFN-gamma with disease progression, aspartate aminotransferase, alanine aminotransferase, and viral load in chronic hepatitis B and C. Int J Infect Dis 17: e44-e49.
103. Kusaba K, Kai H, Koga M, Takayama N, Ikeda A, Yasukawa H, et al. (2007). Inhibition of intrinsic interferon-gamma function prevents neointima formation after balloon injury. Hypertension 49: 909-915.
104. Lallemand C, Blanchard B, Palmieri M, Lebon P, May E, Tovey MG, (2007). Single-stranded RNA viruses inactivate the transcriptional activity of p53 but induce NOXA-dependent apoptosis via post-translational modifications of IRF-1, IRF-3 and CREB. Oncogene 26: 328-338.
105. Lande R, Gilliet M, (2010). Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 1183: 89-103.
106. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, et al. (2012). IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 9: e1003118.
107. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, et al. (2013). IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 9: e1003118.
108. Lazorchak AS, Schlissel MS, Zhuang Y, (2006). E2A and IRF-4/Pip promote chromatin modification and transcription of the immunoglobulin kappa locus in pre-B cells. Mol Cell Biol 26: 810-821.
109. Lehtonen A, Lund R, Lahesmaa R, Julkunen I, Sareneva T, Matikainen S, (2003). IFN-alpha and IL-12 activate IFN regulatory factor 1 (IRF-1), IRF-4, and IRF-8 gene expression in human NK and T-cells. Cytokine 24: 81-90.
110. Leung PY, Stevens SL, Packard AE, Lessov NS, Yang T, Conrad VK, et al. (2012). Toll-like receptor 7 preconditioning induces robust neuroprotection against stroke by a novel type I interferon-mediated mechanism. Stroke 43: 1383-1389.
111. Li H, He C, Feng J, Zhang Y, Tang Q, Bian Z, et al. (2010a). Regulator of G protein signaling 5 protects against cardiac hypertrophy and fibrosis during biomechanical stress of pressure overload. Proc Natl Acad Sci U S A 107: 13818-13823.
112. Li H, Tang QZ, Liu C, Moon M, Chen M, Yan L, et al. (2010b). Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension 56: 1109-1117.
113. Li H, Li H, Bao Y, Zhang X, Yu Y, (2011a). Free fatty acids induce endothelial dysfunction and activate protein kinase C and nuclear factor-kappaB pathway in rat aorta. Int J Cardiol 152: 218-224.
114. Li L, Chen W, Zhu Y, Wang X, Jiang DS, Huang F, et al. (2014). Caspase recruitment domain 6 protects against cardiac hypertrophy in response to pressure overload. Hypertension 64: 94-102.
115. Li S, Wang L, Berman M, Kong YY, Dorf ME, (2011b). Mapping a dynamic innate immunity protein interaction network regulating type I interferon production. Immunity 35: 426-440.
116. Li Z, Wang ZG, Bian C, Chen XD, Li JW, Chen X, et al. (2009). Interferon regulatory factor-1 exerts inhibitory effect on neointimal formation after vascular injury. Chin Med Sci J 24: 91-96.
117. Lim S, Jin CJ, Kim M, Chung SS, Park HS, Lee IK, et al. (2006). PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler Thromb Vasc Biol 26: 808-813.
118. Lin Y, Zhu X, McLntee FL, Xiao H, Zhang J, Fu M, et al. (2004). Interferon regulatory factor-1 mediates PPARgamma-induced apoptosis in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 24: 257-263.
119. Liu CC, Perussia B, Young JD, (2000). The emerging role of IL-15 in NK-cell development. Immunol Today 21: 113-116.
120. Liu Y, Jiang XL, Liu Y, Jiang DS, Zhang Y, Zhang R, et al. (2014). Toll-interacting protein (Tollip) negatively regulates pressure overload-induced ventricular hypertrophy in mice. Cardiovasc Res 101: 87-96.
121. Lu J, Bian ZY, Zhang R, Zhang Y, Liu C, Yan L, et al. (2013a). Interferon regulatory factor 3 is a negative regulator of pathological cardiac hypertrophy. Basic Res Cardiol 108: 326.
122. Lu R, (2008). Interferon regulatory factor 4 and 8 in B-cell development. Trends Immunol 29: 487-492.
123. Lu R, Medina KL, Lancki DW, Singh H, (2003). IRF-4,8 orchestrate the pre-B-to-B transition in lymphocyte development. Genes Dev 17: 1703-1708.
124. Lu YY, Li ZZ, Jiang DS, Wang L, Zhang Y, Chen K, et al. (2013b). TRAF1 is a critical regulator of cerebral ischaemia-reperfusion injury and neuronal death. Nat Commun 4: 2852.
125. Mamane Y, Sharma S, Petropoulos L, Lin R, Hiscott J, (2000). Posttranslational regulation of IRF-4 activity by the immunophilin FKBP52. Immunity 12: 129-140.
126. Marsh B, Stevens SL, Packard AE, Gopalan B, Hunter B, Leung PY, et al. (2009a). Systemic lipopolysaccharide protects the brain from ischemic injury by reprogramming the response of the brain to stroke: a critical role for IRF3. J Neurosci 29: 9839-9849.
127. Marsh BJ, Stenzel-Poore MP, (2008). Toll-like receptors: novel pharmacological targets for the treatment of neurological diseases. Curr Opin Pharmacol 8: 8-13.
128. Marsh BJ, Williams-Karnesky RL, Stenzel-Poore MP, (2009b). Toll-like receptor signaling in endogenous neuroprotection and stroke. Neuroscience 158: 1007-1020.
129. Marsili G, Remoli AL, Sgarbanti M, Battistini A, (2004). Role of acetylases and deacetylase inhibitors in IRF-1-mediated HIV-1 long terminal repeat transcription. Ann N Y Acad Sci 1030: 636-643.
130. Masumi A, (2011). Histone acetyltransferases as regulators of nonhistone proteins: the role of interferon regulatory factor acetylation on gene transcription. J Biomed Biotechnol 2011: 640610.
131. Masumi A, Tamaoki S, Wang IM, Ozato K, Komuro K, (2002). IRF-8/ICSBP and IRF-1 cooperatively stimulate mouse IL-12 promoter activity in macrophages. FEBS Lett 531: 348-353.
132. Masumi A, Yamakawa Y, Fukazawa H, Ozato K, Komuro K, (2003). Interferon regulatory factor-2 regulates cell growth through its acetylation. J Biol Chem 278: 25401-25407.
133. Mellor AL, Munn DH, (2004). IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774.
134. Melroe GT, Silva L, Schaffer PA, Knipe DM, (2007). Recruitment of activated IRF-3 and CBP/p300 to herpes simplex virus ICP0 nuclear foci: Potential role in blocking IFN-beta induction. Virology 360: 305-321.
135. Miano JM, (2003). Serum response factor: toggling between disparate programs of gene expression. J Mol Cell Cardiol 35: 577-593.
136. Mildner A, Chapnik E, Manor O, Yona S, Kim KW, Aychek T, et al. (2013). Mononuclear phagocyte miRNome analysis identifies miR-142 as critical regulator of murine dendritic cell homeostasis. Blood 121: 1016-1027.
137. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudo Y, et al. (1988). Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 54: 903-913.
138. Mori M, Yoneyama M, Ito T, Takahashi K, Inagaki F, Fujita T, (2004). Identification of Ser-386 of interferon regulatory factor 3 as critical target for inducible phosphorylation that determines activation. J Biol Chem 279: 9698-9702.
139. Murphy AA, Rosato PC, Parker ZM, Khalenkov A, Leib DA, (2013). Synergistic control of herpes simplex virus pathogenesis by IRF-3, and IRF-7 revealed through non-invasive bioluminescence imaging. Virology 444: 71-79.
140. Narayan V, Pion E, Landre V, Muller P, Ball KL, (2011). Docking-dependent ubiquitination of the interferon regulatory factor-1 tumor suppressor protein by the ubiquitin ligase CHIP. J Biol Chem 286: 607-619.
141. Negishi H, Ohba Y, Yanai H, Takaoka A, Honma K, Yui K, et al. (2005). Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A 102: 15989-15994.
142. Nguyen H, Hiscott J, Pitha PM, (1997). The growing family of interferon regulatory factors. Cytokine Growth Factor Rev 8: 293-312.
143. Oganesyan G, Saha SK, Guo B, He JQ, Shahangian A, Zarnegar B, et al. (2006). Critical role of TRAF3 in the Toll-like receptor-dependent and -independent antiviral response. Nature 439: 208-211.
144. Oke V, Wahren-Herlenius M, (2012). The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun 39: 77-82.
145. Okumura A, Alce T, Lubyova B, Ezelle H, Strebel K, Pitha PM, (2008). HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation. Virology 373: 85-97.
146. O'Neill LA, Bowie AG, (2007). The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7: 353-364.
147. Panne D, McWhirter SM, Maniatis T, Harrison SC, (2007). Interferon regulatory factor 3 is regulated by a dual phosphorylation-dependent switch. J Biol Chem 282: 22816-22822.
148. Passioura T, Dolnikov A, Shen S, Symonds G, (2005). N-ras-induced growth suppression of myeloid cells is mediated by IRF-1. Cancer Res 65: 797-804.
149. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
150. Pernis AB, (2002). The role of IRF-4 in B and T-cell activation and differentiation. J Interferon Cytokine Res 22: 111-120.
151. Pettersson S, Kelleher M, Pion E, Wallace M, Ball KL, (2009). Role of Mdm2 acid domain interactions in recognition and ubiquitination of the transcription factor IRF-2. Biochem J 418: 575-585.
152. Piao W, Ru LW, Piepenbrink KH, Sundberg EJ, Vogel SN, Toshchakov VY, (2013). Recruitment of TLR adapter TRIF to TLR4 signaling complex is mediated by the second helical region of TRIF TIR domain. Proc Natl Acad Sci U S A 110: 19036-19041.
153. Pinto LA, Michel S, Klopp N, Vogelberg C, von Berg A, Bufe A, et al. (2013). Polymorphisms in the IRF-4 gene, asthma and recurrent bronchitis in children. Clin Exp Allergy 43: 1152-1159.
154. Pion E, Narayan V, Eckert M, Ball KL, (2009). Role of the IRF-1 enhancer domain in signalling polyubiquitination and degradation. Cell Signal 21: 1479-1487.
155. Prakash A, Smith E, Lee CK, Levy DE, (2005). Tissue-specific positive feedback requirements for production of type I interferon following virus infection. J Biol Chem 280: 18651-18657.
156. Purtha WE, Swiecki M, Colonna M, Diamond MS, Bhattacharya D, (2012). Spontaneous mutation of the Dock2 gene in Irf5-/- mice complicates interpretation of type I interferon production and antibody responses. Proc Natl Acad Sci U S A 109: E898-E904.
157. Qi H, Zhu H, Lou M, Fan Y, Liu H, Shen J, et al. (2012). Interferon regulatory factor 1 transactivates expression of human DNA polymerase eta in response to carcinogen N-methyl-N′-nitro-N-nitrosoguanidine. J Biol Chem 287: 12622-12633.
158. Raghavendra Rao VL, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, et al. (2002). Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem 83: 1072-1086.
159. Rengarajan J, Mowen KA, McBride KD, Smith ED, Singh H, Glimcher LH, (2002). Interferon regulatory factor 4 (IRF4) interacts with NFATc2 to modulate interleukin 4 gene expression. J Exp Med 195: 1003-1012.
160. Restivo G, Nguyen BC, Dziunycz P, Ristorcelli E, Ryan RJ, Ozuysal OY, et al. (2011). IRF6 is a mediator of Notch pro-differentiation and tumour suppressive function in keratinocytes. EMBO J 30: 4571-4585.
161. Saira K, Zhou Y, Jones C, (2007). The infected cell protein 0 encoded by bovine herpesvirus 1 (bICP0) induces degradation of interferon response factor 3 and, consequently, inhibits beta interferon promoter activity. J Virol 81: 3077-3086.
162. Saitoh T, Tun-Kyi A, Ryo A, Yamamoto M, Finn G, Fujita T, et al. (2006). Negative regulation of interferon-regulatory factor 3-dependent innate antiviral response by the prolyl isomerase Pin1. Nat Immunol 7: 598-605.
163. Sanbe A, Gulick J, Hanks MC, Liang Q, Osinska H, Robbins J, (2003). Reengineering inducible cardiac-specific transgenesis with an attenuated myosin heavy chain promoter. Circ Res 92: 609-616.
164. Sasai M, Yamamoto M, (2013). Pathogen recognition receptors: ligands and signaling pathways by Toll-like receptors. Int Rev Immunol 32: 116-133.
165. Sato M, Suemori H, Hata N, Asagiri M, Ogasawara K, Nakao K, et al. (2000). Distinct and essential roles of transcription factors IRF-3 and IRF-7 in response to viruses for IFN-alpha/beta gene induction. Immunity 13: 539-548.
166. Savitsky D, Tamura T, Yanai H, Taniguchi T, (2010). Regulation of immunity and oncogenesis by the IRF transcription factor family. Cancer Immunol Immunother 59: 489-510.
167. Scheller M, Schonheit J, Zimmermann K, Leser U, Rosenbauer F, Leutz A, (2013). Cross talk between Wnt/beta-catenin and Irf8 in leukemia progression and drug resistance. J Exp Med 210: 2239-2256.
168. Schiavoni G, Mattei F, Sestili P, Borghi P, Venditti M, Morse HC 3rd, et al. (2002). ICSBP is essential for the development of mouse type I interferon-producing cells and for the generation and activation of CD8alpha(+) dendritic cells. J Exp Med 196: 1415-1425.
169. Schiffrin EL, (2014). Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond) 126: 267-274.
170. Schmitz F, Heit A, Guggemoos S, Krug A, Mages J, Schiemann M, et al. (2007). Interferon-regulatory-factor 1 controls Toll-like receptor 9-mediated IFN-beta production in myeloid dendritic cells. Eur J Immunol 37: 315-327.
171. Sears N, Sen GC, Stark GR, Chattopadhyay S, (2011). Caspase-8-mediated cleavage inhibits IRF-3 protein by facilitating its proteasome-mediated degradation. J Biol Chem 286: 33037-33044.
172. Seth RB, Sun L, Ea C-K, Chen ZJ, (2005). Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-κB and IRF3. Cell 122: 669-682.
173. Shaik-Dasthagirisaheb YB, Huang N, Gibson FC 3rd, (2014). Inflammatory response to Porphyromonas gingivalis partially requires interferon regulatory factor (IRF) 3. Innate Immun 20: 312-319.
174. Sharif-Naeini R, Folgering JH, Bichet D, Duprat F, Delmas P, Patel A, et al. (2010). Sensing pressure in the cardiovascular system: Gq-coupled mechanoreceptors and TRP channels. J Mol Cell Cardiol 48: 83-89.
175. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, et al. (2005). Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 76: 528-537.
176. Soros P, Hachinski V, (2012). Cardiovascular and neurological causes of sudden death after ischaemic stroke. Lancet Neurol 11: 179-188.
177. Stankowski JN, Gupta R, (2011). Therapeutic targets for neuroprotection in acute ischemic stroke: lost in translation? Antioxid Redox Signal 14: 1841-1851.
178. Stevens SL, Leung PY, Vartanian KB, Gopalan B, Yang T, Simon RP, et al. (2011). Multiple preconditioning paradigms converge on interferon regulatory factor-dependent signaling to promote tolerance to ischemic brain injury. J Neurosci 31: 8456-8463.
179. Takaoka A, Yanai H, (2006). Interferon signalling network in innate defence. Cell Microbiol 8: 907-922.
180. Takeda K, Akira S, (2004). TLR signaling pathways. Semin Immunol 16: 3-9.
181. Taki S, Nakajima S, Ichikawa E, Saito T, Hida S, (2005). IFN regulatory factor-2 deficiency revealed a novel checkpoint critical for the generation of peripheral NK cells. J Immunol 174: 6005-6012.
182. Tamura T, Ozato K, (2002). ICSBP/IRF-8: its regulatory roles in the development of myeloid cells. J Interferon Cytokine Res 22: 145-152.
183. Tamura T, Tailor P, Yamaoka K, Kong HJ, Tsujimura H, O'Shea JJ, et al. (2005). IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol 174: 2573-2581.
184. Tamura T, Yanai H, Savitsky D, Taniguchi T, (2008). The IRF family transcription factors in immunity and oncogenesis. Annu Rev Immunol 26: 535-584.
185. Tanaka N, Kawakami T, Taniguchi T, (1993). Recognition DNA sequences of interferon regulatory factor 1 (IRF-1) and IRF-2, regulators of cell growth and the interferon system. Mol Cell Biol 13: 4531-4538.
186. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. (2007a). Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci U S A 104: 13798-13803.
187. Tang X, Gao JS, Guan YJ, McLane KE, Yuan ZL, Ramratnam B, et al. (2007b). Acetylation-dependent signal transduction for type I interferon receptor. Cell 131: 93-105.
188. Taniguchi T, Takaoka A, (2002). The interferon-alpha/beta system in antiviral responses: a multimodal machinery of gene regulation by the IRF family of transcription factors. Curr Opin Immunol 14: 111-116.
189. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N, (2001). IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623-655.
190. Timmers L, Sluijter JP, van Keulen JK, Hoefer IE, Nederhoff MG, Goumans MJ, et al. (2008). Toll-like receptor 4 mediates maladaptive left ventricular remodeling and impairs cardiac function after myocardial infarction. Circ Res 102: 257-264.
191. Tsushima K, Osawa T, Yanai H, Nakajima A, Takaoka A, Manabe I, et al. (2011). IRF3 regulates cardiac fibrosis but not hypertrophy in mice during angiotensin II-induced hypertension. FASEB J 25: 1531-1543.
192. Vartanian KB, Stevens SL, Marsh BJ, Williams-Karnesky R, Lessov NS, Stenzel-Poore MP, (2011). LPS preconditioning redirects TLR signaling following stroke: TRIF-IRF3 plays a seminal role in mediating tolerance to ischemic injury. J Neuroinflammation 8: 140.
193. Vivier E, Raulet DH, Moretta A, Caligiuri MA, Zitvogel L, Lanier LL, et al. (2011). Innate or adaptive immunity? The example of natural killer cells. Science 331: 44-49.
194. Wagner AH, Gebauer M, Pollok-Kopp B, Hecker M, (2002). Cytokine-inducible CD40 expression in human endothelial cells is mediated by interferon regulatory factor-1. Blood 99: 520-525.
195. Wang F, Ma Y, Barrett JW, Gao X, Loh J, Barton E, et al. (2004). Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. Nat Immunol 5: 1266-1274.
196. Wang H, Morse HC 3rd, (2009). IRF8 regulates myeloid and B lymphoid lineage diversification. Immunol Res 43: 109-117.
197. Wang H, Lee CH, Qi C, Tailor P, Feng J, Abbasi S, et al. (2008). IRF8 regulates B-cell lineage specification, commitment, and differentiation. Blood 112: 4028-4038.
198. Wang J, Maldonado MA, (2006). The ubiquitin-proteasome system and its role in inflammatory and autoimmune diseases. Cell Mol Immunol 3: 255-261.
199. Wang J, Yang B, Hu Y, Zheng Y, Zhou H, Wang Y, et al. (2013a). Negative regulation of Nmi on virus-triggered type I IFN production by targeting IRF7. J Immunol 191: 3393-3399.
200. Wang L, Lu Y, Deng S, Zhang Y, Yang L, Guan Y, et al. (2012). SHPS-1 deficiency induces robust neuroprotection against experimental stroke by attenuating oxidative stress. J Neurochem 122: 834-843.
201. Wang L, Lu Y, Zhang X, Zhang Y, Jiang D, Dong X, et al. (2013b). Mindin is a critical mediator of ischemic brain injury in an experimental stroke model. Exp Neurol 247: 506-516.
202. Wang XA, Zhang R, Jiang D, Deng W, Zhang S, Deng S, et al. (2013c). Interferon regulatory factor 9 protects against hepatic insulin resistance and steatosis in male mice. Hepatology 58: 603-616.
203. Wang XA, Zhang R, She ZG, Zhang XF, Jiang DS, Wang T, et al. (2014). Interferon regulatory factor 3 constrains IKKbeta/NF-kappaB signaling to alleviate hepatic steatosis and insulin resistance. Hepatology 59: 870-885.
204. Wang XA, Zhang R, Zhang S, Deng S, Jiang D, Zhong J, et al. (2013d). Interferon regulatory factor 7 deficiency prevents diet-induced obesity and insulin resistance. Am J Physiol Endocrinol Metab 305: E485-E495.
205. Watford WT, Moriguchi M, Morinobu A, O'Shea JJ, (2003). The biology of IL-12: coordinating innate and adaptive immune responses. Cytokine Growth Factor Rev 14: 361-368.
206. Wessely R, Hengst L, Jaschke B, Wegener F, Richter T, Lupetti R, et al. (2003). A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia. Hum Mol Genet 12: 177-187.
207. Woods M, Wood EG, Bardswell SC, Bishop-Bailey D, Barker S, Wort SJ, et al. (2003). Role for nuclear factor-kappaB and signal transducer and activator of transcription 1/interferon regulatory factor-1 in cytokine-induced endothelin-1 release in human vascular smooth muscle cells. Mol Pharmacol 64: 923-931.
208. Xiang M, Wang L, Guo S, Lu YY, Lei H, Jiang DS, et al. (2014). Interferon regulatory factor 8 protects against cerebral ischaemic-reperfusion injury. J Neurochem 129: 988-1001.
209. Xiao J, Moon M, Yan L, Nian M, Zhang Y, Liu C, et al. (2012). Cellular FLICE-inhibitory protein protects against cardiac remodelling after myocardial infarction. Basic Res Cardiol 107: 239.
210. Xiong H, Li H, Kong HJ, Chen Y, Zhao J, Xiong S, et al. (2005). Ubiquitin-dependent degradation of interferon regulatory factor-8 mediated by Cbl down-regulates interleukin-12 expression. J Biol Chem 280: 23531-23539.
211. Xu H, Krolikowski JG, Jones DW, Ge ZD, Pagel PS, Pritchard KA Jr, et al. (2012). 4F decreases IRF5 expression and activation in hearts of tight skin mice. PLoS ONE 7: e52046.
212. Yamamoto M, Kato T, Hotta C, Nishiyama A, Kurotaki D, Yoshinari M, et al. (2011). Shared and distinct functions of the transcription factors IRF4 and IRF8 in myeloid cell development. PLoS ONE 6: e25812.
213. Yan L, Wei X, Tang QZ, Feng J, Zhang Y, Liu C, et al. (2011). Cardiac-specific mindin overexpression attenuates cardiac hypertrophy via blocking AKT/GSK3beta and TGF-beta1-SMAD signalling. Cardiovasc Res 92: 85-94.
214. Yanai H, Negishi H, Taniguchi T, (2012). The IRF family of transcription factors: inception, impact and implications in oncogenesis. Oncoimmunology 1: 1376-1386.
215. Yang J, Hu X, Zimmerman M, Torres CM, Yang D, Smith SB, et al. (2011). Cutting edge: IRF8 regulates Bax transcription in vivo in primary myeloid cells. J Immunol 187: 4426-4430.
216. Yang K, Shi HX, Liu XY, Shan YF, Wei B, Chen S, et al. (2009). TRIM21 is essential to sustain IFN regulatory factor 3 activation during antiviral response. J Immunol 182: 3782-3792.
217. Yang L, Feng D, Bi X, Stone RC, Barnes BJ, (2012). Monocytes from Irf5-/- mice have an intrinsic defect in their response to pristane-induced lupus. J Immunol 189: 3741-3750.
218. Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, et al. (2005). Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. J Immunol 175: 2851-2858.
219. Yoshida T, Sinha S, Dandre F, Wamhoff BR, Hoofnagle MH, Kremer BE, et al. (2003). Myocardin is a key regulator of CArG-dependent transcription of multiple smooth muscle marker genes. Circ Res 92: 856-864.
220. Zhang M, Tian Y, Wang RP, Gao D, Zhang Y, Diao FC, et al. (2008). Negative feedback regulation of cellular antiviral signaling by RBCK1-mediated degradation of IRF3. Cell Res 18: 1096-1104.
221. Zhang SM, Gao L, Zhang XF, Zhang R, Zhu LH, Wang PX, et al. (2014a). Interferon regulatory factor 8 modulates phenotypic switching of smooth muscle cells by regulating the activity of myocardin. Mol Cell Biol 34: 400-414.
222. Zhang SM, Zhu LH, Li ZZ, Wang PX, Chen HZ, Guan HJ, et al. (2014b). Interferon regulatory factor 3 protects against adverse neo-intima formation. Cardiovasc Res 102: 469-479.
223. Zhang Y, Liu X, She ZG, Jiang DS, Wan N, Xia H, et al. (2014c). Interferon regulatory factor 9 is an essential mediator of heart dysfunction and cell death following myocardial ischemia/reperfusion injury. Basic Res Cardiol 109: 434.
224. Zhang Y, Liu Y, Zhu XH, Zhang XD, Jiang DS, Bian ZY, et al. (2014d). Dickkopf-3 attenuates pressure overload-induced cardiac remodelling. Cardiovasc Res 102: 35-45.
225. Zhao GN, Jiang DS, Li H, (2014). Interferon regulatory factors: at the crossroads of immunity, metabolism, and disease. Biochim Biophys Acta doi: 10.1016/j.bbadis.2014.04.030. [Epub ahead of print].
226. Zhou L, Littman DR, (2009). Transcriptional regulatory networks in Th17 cell differentiation. Curr Opin Immunol 21: 146-152.
227. Ziegler G, Harhausen D, Schepers C, Hoffmann O, Rohr C, Prinz V, et al. (2007). TLR2 has a detrimental role in mouse transient focal cerebral ischemia. Biochem Biophys Res Commun 359: 574-579.